Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 6, 2023
Regen BioPharma, Inc. extends a warm invitation to both individual and institutional investors, as well as advisors and analysts, to join us for our live, dynamic presentation at the Emerging Growth Conference.
Regen BioPharma, Inc., a biotech company that is making progress in various areas of pre-clinical research such as cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs, is scheduled to deliver a presentation at the Emerging Growth Conference on September 6, 2023. You can find more information about the conference at this link: https://emerginggrowth.com/conference/.
Join us for this exciting live online event where shareholders and investors can engage in real-time conversations with the Company's CEO, Dr. David Koos. Feel free to ask your questions during the session, and Dr. Koos and his team will make every effort to answer as many as they can.
Dr. David Koos, the Company's CEO and Chairman, states that during this period, their intention is to utilize the opportunity to talk about their recent patent application. This patent application reveals innovative methods for producing CAR-T cells that aim to control autoimmunity. Additionally, they will also address any inquiries or concerns raised by the shareholders.
Regen BioPharma, Inc. has scheduled a presentation for Wednesday, September 6, 2023, from 3:55 pm to 4:05 pm Eastern time. We kindly request you to register at the following link to secure your attendance at the conference and stay updated with any released information: https://goto.webcasts.com/starthere.jsp?ei=1603285&tp_key=ab3efc5870&sti=rgbp.
If participants are unable to attend the event in real-time on the conference day, a recorded online broadcast will also be accessible on EmergingGrowth.com.
Introducing the Emerging Growth Conference
The Rising Development seminar offers a useful avenue for publicly traded businesses to showcase and convey their latest offerings, services, and noteworthy updates to the investment circle without the need to travel, saving precious time.
The blog section discusses various growth sectors, encompassing companies with capable leadership, creative offerings, targeted plans, effective implementation, and promising prospects for sustained expansion. The readership consists of potentially numerous individual and institutional investors, along with investment advisors and analysts.
Introducing Regen BioPharma Inc.:
Regen BioPharma, Inc. is an openly traded biotech organization (PINK: RGBP) and (PINK: RGBPP). The company is dedicated to the field of immunology and immunotherapy. Its primary goal is to quickly progress innovative technologies through early testing and clinical trials. Presently, the focus lies on utilizing mRNA and small molecule treatments to combat cancer and autoimmune diseases. For more details on Regen BioPharma, please visit their website at http://www.regenbiopharmainc.com.
Please note: The following news update might include statements about what may happen in the future. These statements are always uncertain and can't be accurately predicted or measured. The actual outcomes and the events that actually occur may be significantly different from what is expressed or suggested in these future-focused statements. The risks and uncertainties associated with these forward-looking statements include, but are not limited to, government regulations, competition, and other significant risks.
Contact details: Company Name: Regen BioPharma Inc. Name: David R. Koos, Ph.D. Position: Chairman & Chief Executive Officer Phone: +1-619-722-5505 Fax: +1-619-330-2328 Email: [email protected]
Stay connected with us on Twitter for upcoming announcements and news: https://twitter.com/TheRegenBio
Regen BioPharma Incorporated has announced a breakthrough in their latest study.
